{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T19:55:53Z","timestamp":1792007753243,"version":"4.4.0"},"publisher-location":"Cham","reference-count":45,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030220044","type":"print"},{"value":"9783030220051","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/164_2019_227","type":"book-chapter","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T03:03:01Z","timestamp":1560481381000},"page":"283-295","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Obeticholic Acid: An Update of Its Pharmacological Activities in Liver Disorders"],"prefix":"10.1007","author":[{"given":"Stefano","family":"Fiorucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Di Giorgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Distrutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,15]]},"reference":[{"key":"227_CR1002","first-page":"1040","volume":"42","author":"E Albanis","year":"2005","unstructured":"Albanis E, Alvarez CE, Pruzansky M, Friedman SL, Fiorucci S (2005) INT-747, a novel FXR activator, reverses hepatic fibrosis and cirrhosis in thioacetamide-induced liver injury in rats. Hepatology 42:1040. Abs","journal-title":"Hepatology"},{"key":"227_CR1","doi-asserted-by":"publisher","unstructured":"Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA (2018) Nonalcoholic steatohepatitis clinical research network. improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials. Hepatology. \n                  https:\/\/doi.org\/10.1002\/hep.30418","DOI":"10.1002\/hep.30418"},{"key":"227_CR2","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1126\/science.294.5548.1866","volume":"294","author":"A Chawla","year":"2001","unstructured":"Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ (2001) Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866\u20131870","journal-title":"Science"},{"key":"227_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1194\/jlr.M001602","volume":"51","author":"S Cipriani","year":"2010","unstructured":"Cipriani S, Mencarelli A, Palladino G, Fiorucci S (2010) FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa\/fa) obese rats. Journal of Lipid Research 51:771\u2013784","journal-title":"Journal of Lipid Research"},{"key":"227_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1021\/jm401873d","volume":"57","author":"C D\u2019Amore","year":"2014","unstructured":"D\u2019Amore C, Di Leva FS, Sepe V, Renga B, Del Gaudio C, D\u2019Auria MV, Zampella A, Fiorucci S, Limongelli V (2014) Design, synthesis, and biological evaluation of potent dual agonists of nuclear and membrane bile acid receptors. Journal of Medicinal Chemistry 57:937\u2013954","journal-title":"Journal of Medicinal Chemistry"},{"key":"227_CR1000","doi-asserted-by":"publisher","DOI":"10.1007\/164_2019_237","volume-title":"Handbook of experimental pharmacology","author":"S Marino De","year":"2019","unstructured":"De Marino S, festa C, sepe V, Zampella A (2019) Chemistry and pharmacology of GPBAR1 and FXR selective agonists, dual agonists, and antagonists. In: Handbook of experimental pharmacology. Springer Nature Switzerland AG, Basel. \n                  https:\/\/doi.org\/10.1007\/164_2019_237"},{"key":"227_CR1001","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1021\/jm400419e","volume":"56","author":"FS Leva Di","year":"2013","unstructured":"Di Leva FS, Festa C, D\u2019Amore C, De Marino S, Renga B, D\u2019Auria MV, Novellino E, Limongelli V, Zampella A et al (2013) Binding mechanism of the farnesoid X receptor marine antagonist suvanine reveals a strategy to forestall drug modulation on nuclear receptors. Design, synthesis, and biological evaluation of novel ligands. Journal of Medicinal Chemistry 56:4701\u20134717","journal-title":"Journal of Medicinal Chemistry"},{"key":"227_CR6","doi-asserted-by":"publisher","first-page":"8477","DOI":"10.1021\/jm501273r","volume":"57","author":"C Festa","year":"2014","unstructured":"Festa C, Renga B, D\u2019Amore C, Sepe V, Finamore C, De Marino S, Carino A, Cipriani S, Monti MC et al (2014) Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands. Journal of Medicinal Chemistry 57:8477\u20138495","journal-title":"Journal of Medicinal Chemistry"},{"key":"227_CR7","volume-title":"Handbook of Experimental Pharmacology","author":"Stefano Fiorucci","year":"2019","unstructured":"Fiorucci S, Distrutti E (2019) Chenodeoxycholic acid: an update on its therapeutic applications. In: Handbook on experimental pharmacology. Springer, Berlin. \n                  https:\/\/doi.org\/10.1007\/164_2019_226"},{"key":"227_CR8","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1053\/j.gastro.2004.08.001","volume":"127","author":"S Fiorucci","year":"2004","unstructured":"Fiorucci S, Antonelli E, Rizzo G, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pellicciari R, Morelli A (2004) The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 127:1497\u20131512","journal-title":"Gastroenterology"},{"key":"227_CR9","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1124\/jpet.104.079665","volume":"313","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci S, Clerici C, Antonelli E, Orlandi S, Goodwin B, Sadeghpour BM, Sabatino G, Russo G, Castellani D et al (2005a) Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. Journal of Pharmacology and Experimental Therapeutics 313:604\u2013612","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"227_CR10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1124\/jpet.105.085597","volume":"315","author":"S Fiorucci","year":"2005","unstructured":"Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Morelli A, Pruzanski M, Pellicciari R (2005b) Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. Journal of Pharmacology and Experimental Therapeutics 315:58\u201368","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"227_CR11","doi-asserted-by":"publisher","first-page":"753","DOI":"10.2174\/138955711796355258","volume":"11","author":"S Fiorucci","year":"2011","unstructured":"Fiorucci S, Cipriani S, Mencarelli A, Baldelli F, Bifulco G, Zampella A (2011) Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini-Reviews in Medicinal Chemistry 11:753\u2013762","journal-title":"Mini-Reviews in Medicinal Chemistry"},{"key":"227_CR12","first-page":"1449","volume":"18","author":"S Fiorucci","year":"2014","unstructured":"Fiorucci S, Distrutti E, Ricci P, Giuliano V, Donini A, Baldelli F (2014) Targeting FXR in cholestasis: hype or hope. Expert Opinion on Therapeutic Targets 18:1449\u20131459","journal-title":"Expert Opinion on Therapeutic Targets"},{"key":"227_CR13","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.phrs.2018.07.014","volume":"134","author":"S Fiorucci","year":"2018","unstructured":"Fiorucci S, Biagioli M, Distrutti E (2018) Future trends in the treatment of non-alcoholic steatohepatitis. Pharmacol Res. 134:289\u2013298","journal-title":"Pharmacol Res."},{"key":"227_CR14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/0092-8674(95)90530-8","volume":"81","author":"BM Forman","year":"1995","unstructured":"Forman BM, Goode E, Chen J, Oro AE, Bradley DJ, Perlmann T, Noonan DJ, Burka LT, McMorris T et al (1995) Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 81:687\u2013693","journal-title":"Cell"},{"issue":"13","key":"227_CR15","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1038\/s41388-018-0591-7","volume":"38","author":"Lixia Gao","year":"2018","unstructured":"Gao L, Lang L, Zhao X, Shay C, Shull AY, Teng Y (2018) FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19\/FGFR4 signaling in head and neck squamous cell carcinoma. Oncogene. \n                  https:\/\/doi.org\/10.1038\/s41388-018-0591-7","journal-title":"Oncogene"},{"key":"227_CR16","volume-title":"Handbook on experimental pharmacology","author":"L Guo","year":"2019","unstructured":"Guo L (2019) FXR agonists for the treatment of NASH and other metabolic disorders. In: Handbook on experimental pharmacology. Springer, Berlin"},{"key":"227_CR17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/apt.14492","volume":"47","author":"B Hameed","year":"2018","unstructured":"Hameed B, Terrault NA, Gill RM, Loomba R, Chalasani N, Hoofnagle JH, Van Natta ML (2018) NASH CRN. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics 47:645\u2013656","journal-title":"Alimentary Pharmacology and Therapeutics"},{"key":"227_CR18","volume-title":"Handbook on experimental pharmacology","author":"D Haussinger","year":"2019","unstructured":"Haussinger D, Keitel V (2019) Targeting FXR in cholestasi. In: Handbook on experimental pharmacology. Springer, Berlin"},{"key":"227_CR19","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","volume":"148","author":"GM Hirschfield","year":"2015","unstructured":"Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, Kowdley KV, Vincent C, Bodhenheimer HC Jr et al (2015) Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148:751\u2013761","journal-title":"Gastroenterology"},{"key":"227_CR20","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1126\/science.1198363","volume":"331","author":"S Kir","year":"2011","unstructured":"Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA et al (2011) FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331:1621\u20131624","journal-title":"Science"},{"key":"227_CR21","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1002\/hep.29569","volume":"67","author":"KV Kowdley","year":"2018","unstructured":"Kowdley KV, Luketic V, Chapman R, Hirschfield GM, Poupon R, Schramm C, Vincent C, Rust C, Par\u00e9s A et al (2018) Obeticholic acid PBC monotherapy study group. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology 67:1890\u20131902","journal-title":"Hepatology"},{"key":"227_CR22","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.3390\/cells8010031","volume":"8","author":"L Lang","year":"2019","unstructured":"Lang L, Teng Y (2019) Fibroblast growth factor receptor 4 targeting in cancer: new insights into mechanisms and therapeutic strategies. Cells 8:e31","journal-title":"Cells"},{"key":"227_CR23","doi-asserted-by":"publisher","unstructured":"Lin ZZ, Hsu C, Jeng YM, Hu FC, Pan HW, Wu YM, Hsu HC, Cheng AL (2019) Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma. Liver Int. \n                  https:\/\/doi.org\/10.1111\/liv.14055","DOI":"10.1111\/liv.14055"},{"key":"227_CR24","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1126\/science.284.5418.1362","volume":"284","author":"M Makishima","year":"1999","unstructured":"Makishima M, Okamoto AY, Repa JJ, Tu H, Learned RM, Luk A, Hull MV, Lustig KD, Mangelsdorf DJ et al (1999) Identification of a nuclear receptor for bile acids. Science 284:1362\u20131365","journal-title":"Science"},{"key":"227_CR25","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1021\/jm0002127","volume":"43","author":"PR Maloney","year":"2000","unstructured":"Maloney PR, Parks DJ, Haffner CD, Fivush AM, Chandra G, Plunket KD, Creech KL, Moore LB, Wilson JG et al (2000) Identification of a chemical tool for the orphan nuclear receptor FXR. Journal of Medicinal Chemistry 43:2971\u20132974","journal-title":"Journal of Medicinal Chemistry"},{"key":"227_CR26","doi-asserted-by":"publisher","first-page":"H272","DOI":"10.1152\/ajpheart.01075.2008","volume":"296","author":"A Mencarelli","year":"2009","unstructured":"Mencarelli A, Renga B, Distrutti E, Fiorucci S (2009a) Antiatherosclerotic effect of farnesoid X receptor. American Journal of Physiology-Heart and Circulatory Physiology 296:H272\u2013H281","journal-title":"American Journal of Physiology-Heart and Circulatory Physiology"},{"key":"227_CR27","doi-asserted-by":"publisher","first-page":"6657","DOI":"10.4049\/jimmunol.0901347","volume":"183","author":"A Mencarelli","year":"2009","unstructured":"Mencarelli A, Renga B, Migliorati M, Cipriani S, Distrutti E, Santucci L, Fiorucci S (2009b) The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. Journal of Immunology 183:6657\u20136666","journal-title":"Journal of Immunology"},{"key":"227_CR28","volume-title":"Handbook on experimental pharmacology","author":"A Moschetta","year":"2019","unstructured":"Moschetta A et al (2019) The intestinal enterokine fibroblast growth factor15\/19 in bile acid metabolism. In: Handbook on experimental pharmacology. Springer, Berlin"},{"key":"227_CR29","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1053\/j.gastro.2013.05.042","volume":"145","author":"S Mudaliar","year":"2013","unstructured":"Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P et al (2013) Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 145:574\u2013582","journal-title":"Gastroenterology"},{"key":"227_CR30","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, Chalasani N, Dasarathy S, Diehl AM et al (2015) NASH Clinical Research Network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 385:956\u2013965","journal-title":"Lancet"},{"key":"227_CR31","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1056\/NEJMoa1509840","volume":"375","author":"F Nevens","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P et al (2016) A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. New England Journal of Medicine 375:631\u2013643","journal-title":"New England Journal of Medicine"},{"key":"227_CR32","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1126\/science.284.5418.1365","volume":"284","author":"DJ Parks","year":"1999","unstructured":"Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM et al (1999) Bile acids: natural ligands for an orphan nuclear receptor. Science 284:1365\u20131368","journal-title":"Science"},{"key":"227_CR33","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1021\/jm025529g","volume":"45","author":"R Pellicciari","year":"2002","unstructured":"Pellicciari R, Fiorucci S, Camaioni E, Clerici C, Costantino G, Maloney PR, Morelli A, Parks DJ, Willson TM (2002) 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. Journal of Medicinal Chemistry 45:3569\u20133572","journal-title":"Journal of Medicinal Chemistry"},{"key":"227_CR34","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.cmet.2011.03.019","volume":"13","author":"MJ Potthoff","year":"2011","unstructured":"Potthoff MJ, Boney-Montoya J, Choi M, He T, Sunny NE, Satapati S, Suino-Powell K, Xu HE, Gerard RD et al (2011) FGF15\/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1\u03b1 pathway. Cell Metabolism 13:729\u2013738","journal-title":"Cell Metabolism"},{"key":"227_CR35","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.3748\/wjg.15.2097","volume":"15","author":"B Renga","year":"2009","unstructured":"Renga B, Mencarelli A, Migliorati M, Distrutti E, Fiorucci S (2009) Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. World Journal of Gastroenterology 15:2097\u20132108","journal-title":"World Journal of Gastroenterology"},{"key":"227_CR36","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1124\/mol.110.064501","volume":"78","author":"G Rizzo","year":"2010","unstructured":"Rizzo G, Passeri D, De Franco F, Ciaccioli G, Donadio L, Rizzo G, Orlandi S, Sadeghpour B, Wang XX et al (2010) Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Molecular Pharmacology 78:617\u2013630","journal-title":"Molecular Pharmacology"},{"key":"227_CR37","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1080\/13543776.2018.1459569","volume":"28","author":"V Sepe","year":"2018","unstructured":"Sepe V, Distrutti E, Fiorucci S, Zampella A (2018) Farnesoid X receptor modulators 2014-present: a patent review. Expert Opinion on Therapeutic Patents 28:351\u2013364","journal-title":"Expert Opinion on Therapeutic Patents"},{"key":"227_CR38","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S0092-8674(00)00062-3","volume":"102","author":"CJ Sinal","year":"2000","unstructured":"Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ (2000) Targeted disruption of the nuclear receptor FXR\/BAR impairs bile acid and lipid homeostasis. Cell 102:731\u2013744","journal-title":"Cell"},{"key":"227_CR39","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.4049\/jimmunol.0803978","volume":"183","author":"P Vavassori","year":"2009","unstructured":"Vavassori P, Mencarelli A, Renga B, Distrutti E, Fiorucci S (2009) The bile acid receptor FXR is a modulator of intestinal innate immunity. Journal of Immunology 183:6251\u20136261","journal-title":"Journal of Immunology"},{"key":"227_CR40","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/hep.26939","volume":"59","author":"L Verbeke","year":"2014","unstructured":"Verbeke L, Farre R, Trebicka J, Komuta M, Roskams T, Klein S, Elst IV, Windmolders P, Vanuytsel T et al (2014) Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59:2286\u20132298","journal-title":"Hepatology"},{"key":"227_CR41","doi-asserted-by":"publisher","first-page":"33453","DOI":"10.1038\/srep33453","volume":"6","author":"L Verbeke","year":"2016","unstructured":"Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, Mazzone M et al (2016) FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Scientific Reports 6:33453","journal-title":"Scientific Reports"},{"key":"227_CR43","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1097-2765(00)80348-2","volume":"3","author":"H Wang","year":"1999","unstructured":"Wang H, Chen J, Hollister K, Sowers LC, Forman BM (1999) Endogenous bile acids are ligands for the nuclear receptor FXR\/BAR. Mol Cell 3:543\u2013553","journal-title":"Mol Cell"},{"key":"227_CR44","volume-title":"Handbook on experimental pharmacology","author":"A Zampella","year":"2019","unstructured":"Zampella A (2019) Chemistry and pharmacology of GPBAR and FXR selective agonists, dual agonists and antagonists. In: Handbook on experimental pharmacology. Springer, Berlin"}],"container-title":["Handbook of Experimental Pharmacology","Bile Acids and Their Receptors"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2019_227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,3]],"date-time":"2019-09-03T03:20:27Z","timestamp":1567480827000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2019_227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030220044","9783030220051"],"references-count":45,"URL":"https:\/\/doi.org\/10.1007\/164_2019_227","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"15 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}